PURPOSE: Women with early-onset (age ≤40 years) breast cancer are at high risk of carrying deleterious mutations in the BRCA1/2 genes; genetic assessment is thus recommended. Knowledge of BRCA1/2 mutation status is useful in guiding treatment decisions. To date, there has been no national study of BRCA1/2 testing among newly diagnosed women. METHODS: We used administrative data (2004-2007) from a national sample of 14.4 million commercially insured patients to identify newly diagnosed, early-onset breast cancer cases among women aged 20-40 years (n = 1474). Cox models assessed BRCA1/2 testing, adjusting for covariates and differential lengths of follow-up. RESULTS: Overall, 30% of women aged 40 years or younger received BRCA1/2 testing. In adjusted analyses, women of Jewish ethnicity were significantly more likely to be tested (hazard ratio = 2.83, 95% confidence interval: 1.52-5.28), whereas black women (hazard ratio = 0.34, 95% 0.18-0.64) and Hispanic women (hazard ratio = 0.52, 95% confidence interval: 0.33-0.81) were significantly less likely to be tested than non-Jewish white women. Those enrolled in a health maintenance organization (hazard ratio = 0.73, 95% confidence interval: 0.54-0.99) were significantly less likely to receive BRCA1/2 testing than those point of service insurance plans. Testing rates increased sharply for women diagnosed in 2007 compared with 2004. CONCLUSIONS: In this national sample of patients with newly diagnosed breast cancer at high risk for BRCA1/2 mutations, genetic assessment was low, with marked racial differences in testing.
PURPOSE: Women with early-onset (age ≤40 years) breast cancer are at high risk of carrying deleterious mutations in the BRCA1/2 genes; genetic assessment is thus recommended. Knowledge of BRCA1/2 mutation status is useful in guiding treatment decisions. To date, there has been no national study of BRCA1/2 testing among newly diagnosed women. METHODS: We used administrative data (2004-2007) from a national sample of 14.4 million commercially insured patients to identify newly diagnosed, early-onset breast cancer cases among women aged 20-40 years (n = 1474). Cox models assessed BRCA1/2 testing, adjusting for covariates and differential lengths of follow-up. RESULTS: Overall, 30% of women aged 40 years or younger received BRCA1/2 testing. In adjusted analyses, women of Jewish ethnicity were significantly more likely to be tested (hazard ratio = 2.83, 95% confidence interval: 1.52-5.28), whereas black women (hazard ratio = 0.34, 95% 0.18-0.64) and Hispanic women (hazard ratio = 0.52, 95% confidence interval: 0.33-0.81) were significantly less likely to be tested than non-Jewish white women. Those enrolled in a health maintenance organization (hazard ratio = 0.73, 95% confidence interval: 0.54-0.99) were significantly less likely to receive BRCA1/2 testing than those point of service insurance plans. Testing rates increased sharply for women diagnosed in 2007 compared with 2004. CONCLUSIONS: In this national sample of patients with newly diagnosed breast cancer at high risk for BRCA1/2 mutations, genetic assessment was low, with marked racial differences in testing.
Authors: Kelly Metcalfe; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Ivo Olivotto; Ellen Warner; Olufunmilayo I Olopade; Andrea Eisen; Barbara Weber; Jane McLennan; Ping Sun; William D Foulkes; Steven A Narod Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: Romana Hasnain-Wynia; David W Baker; David Nerenz; Joe Feinglass; Anne C Beal; Mary Beth Landrum; Raj Behal; Joel S Weissman Journal: Arch Intern Med Date: 2007-06-25
Authors: Jessica T DeFrank; J Michael Bowling; Barbara K Rimer; Jennifer M Gierisch; Celette Sugg Skinner Journal: Prev Chronic Dis Date: 2007-06-15 Impact factor: 2.830
Authors: Christina A Clarke; Theresa H M Keegan; Juan Yang; David J Press; Allison W Kurian; Anish H Patel; James V Lacey Journal: J Natl Cancer Inst Date: 2012-07-05 Impact factor: 13.506
Authors: Maija Reblin; Monica L Kasting; Kelli Nam; Courtney L Scherr; Jongphil Kim; Ram Thapa; Cathy D Meade; M Catherine Lee; Tuya Pal; Gwendolyn P Quinn; Susan T Vadaparampil Journal: Breast J Date: 2018-11-28 Impact factor: 2.431
Authors: Tuya Pal; Devon Bonner; Deborah Cragun; Alvaro N A Monteiro; Catherine Phelan; Lily Servais; Jongphil Kim; Steven A Narod; Mohammad R Akbari; Susan T Vadaparampil Journal: Cancer Date: 2015-08-19 Impact factor: 6.860